Ruediger B Mueller
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.
Riek M, Scherer A, Möller B, Ciurea A, Von Mühlenen I, Gabay C, Kyburz D, Brulhart L, von Kempis J, Mueller R, Hasler P, Strahm T, von Känel S, Zufferey P, Dudler J, Finckh A. Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. Sci Rep 2023; 13:17776.
Oct 18, 2023Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.
Oct 18, 2023Sci Rep 2023; 13:17776
Riek Myriam, Scherer Almut, Möller Burkhard, Ciurea Adrian, Von Mühlenen Ines, Gabay Cem, Kyburz Diego, Brulhart Laure, von Kempis Johannes, Mueller Ruediger B, Hasler Paul, Strahm Tanja, von Känel Sabine, Zufferey Pascal, Dudler Jean, Finckh Axel
Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
Mueller R, Schulze-Koops H, Furst D, Cohen S, Kwok K, Wang L, Killeen T, von Kempis J. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel). Clin Rheumatol 2022; 41:1045-1055.
Jan 1, 2022Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
Jan 1, 2022Clin Rheumatol 2022; 41:1045-1055
Mueller Ruediger B, Schulze-Koops Hendrik, Furst Daniel E, Cohen Stanley B, Kwok Kenneth, Wang Lisy, Killeen Tim, von Kempis Johannes
Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high worsening of patient-related outcomes
Thalmann R, von Kempis J, Zgraggen A, Schiff M, Sokka T, Dietrich T, Schulze-Koops H, Mueller R. Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high worsening of patient-related outcomes. Clin Exp Rheumatol 2021
May 5, 2021Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high worsening of patient-related outcomes
May 5, 2021Clin Exp Rheumatol 2021
Thalmann Reto, von Kempis Johannes, Zgraggen Armin, Schiff Michael, Sokka Tuulliki, Dietrich Tobias, Schulze-Koops Hendrik, Mueller Ruediger B
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
Mueller R, Schulze-Koops H, Rubbert-Roth A, Hasler P, Souza A, Durmisi M, Mattow F, Popp F, Hasler C, von Kempis J. Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts. J Clin Med 2019; 8
Sep 26, 2019Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
Sep 26, 2019J Clin Med 2019; 8
Mueller Ruediger B, Schulze-Koops Hendrik, Rubbert-Roth Andrea, Hasler Paul, Souza Alexander, Durmisi Mirsada, Mattow Frederik, Popp Florian, Hasler Caroline, von Kempis Johannes
Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland
von Kempis J, Duetsch S, Reuschling N, Villiger R, Villiger P, Vallelian F, Schaer D, Mueller R. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland. Swiss Med Wkly 2019; 149:w20022.
Mar 10, 2019Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland
Mar 10, 2019Swiss Med Wkly 2019; 149:w20022
von Kempis Johannes, Duetsch Sabine, Reuschling Nicola, Villiger Rahel, Villiger Peter M, Vallelian Florence, Schaer Dominik J, Mueller Ruediger B
51-year-old man with with acute coronary syndrome and bipulmonary infiltrates
von Kempis J, Deutsche S, Reschling N, Villiger R, Villiger P, Vallelian F, Scher D, Mueller R. 51-year-old man with with acute coronary syndrome and bipulmonary infiltrates. Swiss Medical Weekly 2019; 2019;149:w20022
Mar 10, 201951-year-old man with with acute coronary syndrome and bipulmonary infiltrates
Mar 10, 2019Swiss Medical Weekly 2019; 2019;149:w20022
von Kempis Johannes, Deutsche Sabine, Reschling Nicola, Villiger Rahel, Villiger Peter M, Vallelian Florence, Scher Dominik, Mueller Ruediger B
Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
Mueller R, Spaeth M, von Restorff C, Ackermann C, Schulze-Koops H, von Kempis J. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. J Clin Med 2019; 8
Mar 3, 2019Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
Mar 3, 2019J Clin Med 2019; 8
Mueller Ruediger B, Spaeth Michael, von Restorff Cord, Ackermann Christoph, Schulze-Koops Hendrik, von Kempis Johannes
Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation
Pirker I, Krane-Nuber J, Albrich W, Mueller R, Neumann T. Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation. BMC Rheumatology 2018; 2
Nov 3, 2018Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation
Nov 3, 2018BMC Rheumatology 2018; 2
Pirker Ian F J, Krane-Nuber Jacqueline, Albrich Werner, Mueller Ruediger B, Neumann Thomas
Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort
Mueller R, Kaegi T, Haile S, Schulze-Koops H, Schiff M, von Kempis J. Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort. RMD Open 2018; 4:e000673.
Jun 6, 2018Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort
Jun 6, 2018RMD Open 2018; 4:e000673
Mueller Ruediger B, Kaegi Toni, Haile Sarah R, Schulze-Koops Hendrik, Schiff Michael, von Kempis Johannes
Improvement of primary biliary cholangitis (PBC) under treatment with sulfasalazine and abatacept
Popp F, Semela D, von Kempis J, Mueller R. Improvement of primary biliary cholangitis (PBC) under treatment with sulfasalazine and abatacept. BMJ Case Rep 2018; 2018
May 12, 2018Improvement of primary biliary cholangitis (PBC) under treatment with sulfasalazine and abatacept
May 12, 2018BMJ Case Rep 2018; 2018
Popp Florian, Semela David, von Kempis Johannes, Mueller Ruediger B